Evidence map›Paper›PMID 28577549›Full record

ArticleBMC cancer2017

Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma.

Sophie Sneddon, Ann-Marie Patch, Ian M Dick, Stephen Kazakoff, John V Pearson, Nicola Waddell, Richard J N Allcock, Robert A Holt, Bruce W S Robinson, Jenette Creaney

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Genomics and Functional Genomics of Malignant Pleural Mesothelioma.International journal of molecular sciences · 2020
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Sophie SneddonNational Centre for Asbestos Related Disease, School of Medicine and Pharmacology, QEII Medical Centre, University of Western Australia, QQ Block, 6 Verdun Street, Nedlands, WA, 6009, Australia.
Ann-Marie PatchQIMR Berghofer Medical Research Institute, Brisbane, Brisbane, QLD, 4006, Australia.
Ian M DickNational Centre for Asbestos Related Disease, School of Medicine and Pharmacology, QEII Medical Centre, University of Western Australia, QQ Block, 6 Verdun Street, Nedlands, WA, 6009, Australia.
Stephen KazakoffQIMR Berghofer Medical Research Institute, Brisbane, Brisbane, QLD, 4006, Australia.
John V PearsonQIMR Berghofer Medical Research Institute, Brisbane, Brisbane, QLD, 4006, Australia.
Nicola WaddellQIMR Berghofer Medical Research Institute, Brisbane, Brisbane, QLD, 4006, Australia.
Richard J N AllcockSchool of Pathology and Laboratory Medicine, University of Western Australia, Nedlands, WA, 6009, Australia.
Robert A HoltMichael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada.
Bruce W S RobinsonNational Centre for Asbestos Related Disease, School of Medicine and Pharmacology, QEII Medical Centre, University of Western Australia, QQ Block, 6 Verdun Street, Nedlands, WA, 6009, Australia.
Jenette CreaneyNational Centre for Asbestos Related Disease, School of Medicine and Pharmacology, QEII Medical Centre, University of Western Australia, QQ Block, 6 Verdun Street, Nedlands, WA, 6009, Australia. jenette.creaney@uwa.edu.au.
QIMR Berghofer Medical Research Institute · AUUniversity of Western Australia · AUCanada's Michael Smith Genome Sciences Centre · CAQueen Elizabeth II Medical Centre · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMalignant mesothelioma (MM) is an aggressive cancer of the pleural and peritoneal cavities caused by exposure to asbestos. Asbestos-induced mesotheliomas in wild-type mice have been used extensively as a preclinical model because they are phenotypically identical to their human counterpart. However, it is not known if the genetic lesions in these mice tumours are similar to in the human disease, a prerequisite for any new preclinical studies that target genetic abnormalities.

methodsWe performed whole exome sequencing of fifteen asbestos-induced murine MM tumour cell lines from BALB/c, CBA and C57BL/6 mouse strains and compared the somatic mutations and copy number variations with those recurrently reported in human MM. We then catalogued and characterised the mutational landscape of the wild-type murine MM tumours. Quantitative RT-PCR was used to interrogate the expression of key MM genes of interest in the mRNA.

resultsConsistent with human MM tumours, we identified homozygous loss of the tumour suppressor Cdkn2a in 14/15 tumours. One tumour retained the first exon of both of the p16INK4a and p19ARF isoforms though this tumour also contained genetic amplification of Myc resulting in increased expression of the c-Myc proto-oncogene in the mRNA. There were no chromosomal losses in either the Bap1 or Nf2 regions. One tumour harbored homozygous loss of Trp53 in the DNA. Mutation rates were similar in tumours generated in the CBA and C57BL/6 strains when compared to human MM. Interestingly, all BALB/c tumour lines displayed high mutational loads, consistent with the known mutator phenotype of the host strain. The Wnt, MAPK and Jak-STAT signaling pathways were found to be the most commonly affected biological pathways. Mutations and copy number deletions also occurred in the Hedgehog and Hippo pathways.

conclusionsThese data suggest that in the wild-type murine model asbestos causes mesotheliomas in a similar way to in human MM. This further supports the notion that the murine model of MM represents a genuine homologue of the human disease, something uncommon in cancer, and is thus a valuable tool to provide insight into MM tumour development and to aide the search for novel therapeutic strategies.

Indexed as

Exome SequencingAnimalsAsbestosDisease Models, AnimalDNA Copy Number VariationsGenetic Predisposition to DiseaseHumansLung NeoplasmsMesotheliomaMesothelioma, MalignantMiceMutationNeoplasm ProteinsProto-Oncogene MasSignal TransductionAsbestosMAS1 protein, humanNeoplasm ProteinsProto-Oncogene MasAsbestosCdkn2aExome sequencingMesotheliomaMouse modelWild-type

Identifiers

PMID28577549
PMCPMC5455120
OpenAlexW2620980412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.